Coadministration of Voriconazole and Rifabutin Can Increase the Risk of Adverse Drug Reactions in Patients with Multiple Infections.
Yoonjin KimSungyeun BaeKi Young HuhJong Sun JooJikyo LeeSang Hoon SongKyung-Sang YuIn-Jin JangJaeseong OhPublished in: Therapeutic drug monitoring (2024)
Concurrent use of rifabutin and voriconazole was associated with ADRs, including the time from the start of the Q wave to the end of the T wave prolongation, hallucinations, and severe nausea. Moreover, initially, there was a significant decrease in voriconazole concentrations; however, these concentrations substantially increased during septic shock. Therefore, it is essential to monitor drug concentrations and ADRs during concurrent use of voriconazole and rifabutin.